{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T10:37:50Z","timestamp":1787999870854,"version":"build-2784847793"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T00:00:00Z","timestamp":1501113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["mcpiqojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings: Innovations, Quality & Outcomes"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.mayocpiqo.2017.07.004","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T15:03:05Z","timestamp":1504278185000},"page":"192-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Brachial Plexus Neuritis Associated With Anti\u2013Programmed Cell Death-1 Antibodies: Report of 2 Cases"],"prefix":"10.1016","volume":"1","author":[{"given":"Reem M.","family":"Alhammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanna S.","family":"Dronca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Kottschade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi J.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan P.","family":"Staff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Mauermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Tracy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.mayocpiqo.2017.07.004_bib1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/nrneurol.2010.160","article-title":"Chemotherapy-induced peripheral neurotoxicity","volume":"6","author":"Cavaletti","year":"2010","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2017.07.004_bib2","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/annonc\/mdv182","article-title":"A\u00a0systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors","volume":"26","author":"Chen","year":"2015","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.mayocpiqo.2017.07.004_bib3","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2017.07.004_bib4","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s10147-016-0959-z","article-title":"PD-1\/PD-L1 blockade in cancer treatment: perspectives and issues","volume":"21","author":"Hamanishi","year":"2016","journal-title":"Int J Clin Oncol"},{"issue":"26","key":"10.1016\/j.mayocpiqo.2017.07.004_bib5","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocpiqo.2017.07.004_bib6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","article-title":"Coinhibitory pathways in immunotherapy for cancer","volume":"34","author":"Baumeister","year":"2016","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2017.07.004_bib7","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2017.07.004_bib8","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"issue":"19","key":"10.1016\/j.mayocpiqo.2017.07.004_bib9","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.mayocpiqo.2017.07.004_bib10","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/intimm\/dxm091","article-title":"Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs","volume":"19","author":"Wong","year":"2007","journal-title":"Int Immunol"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2017.07.004_bib11","first-page":"169","article-title":"PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer","volume":"35","author":"Dulos","year":"2012","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.mayocpiqo.2017.07.004_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.mayocpiqo.2017.07.004_bib13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/B978-0-444-63432-0.00023-2","article-title":"Autoimmune-mediated peripheral neuropathies and autoimmune pain","volume":"133","author":"Klein","year":"2016","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.mayocpiqo.2017.07.004_bib14","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2017.07.004_bib15","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/mus.25163","article-title":"Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer","volume":"54","author":"Polat","year":"2016","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2017.07.004_bib16","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/annonc\/mdw655","article-title":"Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm","volume":"28","author":"Haddox","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.mayocpiqo.2017.07.004_bib17","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdw126","article-title":"Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma","volume":"27","author":"Vallet","year":"2016","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2017.07.004_bib18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/annonc\/mdw613","article-title":"Vasculitic neuropathy induced by pembrolizumab","volume":"28","author":"Aya","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2017.07.004_bib19","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1515584","article-title":"Pembrolizumab-induced demyelinating polyradiculoneuropathy","volume":"375","author":"de Maleissye","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2017.07.004_bib20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1001\/archneur.1972.00490140013004","article-title":"Natural history of brachial plexus neuropathy: report on 99 patients","volume":"27","author":"Tsairis","year":"1972","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2017.07.004_bib21","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1212\/WNL.46.2.559","article-title":"Immune brachial plexus neuropathy: suggestive evidence for an inflammatory-immune pathogenesis","volume":"46","author":"Suarez","year":"1996","journal-title":"Neurology"}],"container-title":["Mayo Clinic Proceedings: Innovations, Quality & Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454817300425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454817300425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:07:35Z","timestamp":1762870055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542454817300425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S2542454817300425"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2017.07.004","relation":{},"ISSN":["2542-4548"],"issn-type":[{"value":"2542-4548","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brachial Plexus Neuritis Associated With Anti\u2013Programmed Cell Death-1 Antibodies: Report of 2 Cases","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings: Innovations, Quality & Outcomes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2017.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}